Recommendations for Orthostatic Hypotension Already on Midodrine
For a patient already taking midodrine for orthostatic hypotension, optimize the midodrine dose first (up to 10 mg three times daily), then add droxidopa or fludrocortisone as second-line pharmacotherapy while ensuring non-pharmacological measures are maximized. 1
Algorithmic Approach to Management
Step 1: Optimize Current Midodrine Therapy
- Verify dosing: Ensure midodrine is dosed at 2.5-10 mg three times daily, with the last dose no later than 4-6 PM to minimize supine hypertension 2
- Check timing: First dose should be taken before arising in the morning 3
- Titrate upward: If symptoms persist and supine hypertension is not present, increase dose incrementally to maximum 10 mg three times daily 1, 4
- Monitor for side effects: Assess for scalp tingling, piloerection, urinary retention, and most importantly, supine hypertension 1, 2
Step 2: Maximize Non-Pharmacological Interventions
These should be implemented regardless of medication regimen:
- Compression garments: Waist-high or thigh-high compression stockings (shorter garments are ineffective) 1
- Physical counter-pressure maneuvers: Leg crossing, squatting, lower body muscle tensing when symptoms occur 1
- Acute water ingestion: 480 mL of water provides peak effect at 30 minutes for temporary relief (avoid glucose or salt additives which reduce effectiveness) 1
- Head-up sleeping: Elevate head of bed 10-15 cm (4-6 inches) to prevent nocturnal polyuria and reduce supine hypertension 3, 5
- Salt and fluid loading: 6-9 g sodium daily (1-2 teaspoons table salt) and 2-3 liters fluid daily, unless contraindicated by heart failure, renal disease, or hypertension 1, 5
Step 3: Add Second-Line Pharmacotherapy
If symptoms persist despite optimized midodrine and non-pharmacological measures:
Option A - Droxidopa (Preferred for neurogenic OH):
- Start 100 mg three times daily, titrate to maximum 600 mg three times daily 1, 4
- Particularly effective in Parkinson disease, pure autonomic failure, and multiple system atrophy 1
- May reduce falls 1
- Caution: Carbidopa decreases droxidopa effectiveness in Parkinson patients 1
- Monitor for supine hypertension, headache, dizziness, nausea 1, 4
Option B - Fludrocortisone:
- Start 0.1 mg daily at night, titrate to 0.1-0.3 mg daily 1, 5, 6
- Increases plasma volume through sodium retention 1
- Critical caveat: Should NOT be used if supine hypertension is present; other medications should be tried first 1
- Monitor for edema, hypokalemia, headache 1
- Doses >0.3 mg daily risk adrenal suppression and immunosuppression 1
- Contraindicated or poorly tolerated in heart failure 4
Step 4: Refractory Cases - Third-Line Options
Pyridostigmine:
- 30-60 mg two to three times daily 1, 4, 7
- Increases peripheral vascular resistance without causing supine hypertension 1, 4
- Side effects: nausea, vomiting, abdominal cramping, sweating, salivation, urinary incontinence 1
- Best for patients who cannot tolerate supine hypertension from other agents 4
Octreotide:
- For refractory postprandial or neurogenic OH 1, 7
- Reduces splanchnic blood flow by ~20% 1
- Requires careful monitoring for hypertensive episodes 6
Critical Pitfalls to Avoid
Supine Hypertension Management:
- This is the primary limiting factor for all pressor agents 1, 6, 2
- Patients must avoid becoming fully supine; sleep with head elevated 2
- Last midodrine dose must be 3-4 hours before bedtime 1, 3, 2
- If supine BP >180/110 mmHg, consider short-acting antihypertensives at bedtime 8
- Fludrocortisone should be avoided entirely if supine hypertension exists 1
Medication Interactions:
- Avoid combining with other vasoconstrictors (phenylephrine, ephedrine, pseudoephedrine, dihydroergotamine) 2
- Use caution with cardiac glycosides, beta-blockers, psychotropic agents that reduce heart rate 2
- Monitor for bradycardia; discontinue if pulse slowing, increased dizziness, or syncope occurs 2
Special Populations:
- Renal impairment: Start midodrine at 2.5 mg; desglymidodrine is renally eliminated 2
- Heart failure patients: Salt tablets, fludrocortisone poorly tolerated; prefer pyridostigmine 4
- Diabetics: Use caution, especially with concurrent fludrocortisone (increases intraocular pressure/glaucoma risk) 2
Evidence Quality Considerations
The 2017 ACC/AHA/HRS guidelines 1, 9, 7 provide the strongest framework, giving midodrine and droxidopa Class IIa recommendations with Level B-R evidence for neurogenic OH. Fludrocortisone receives Class IIa with Level C-LD (lower quality evidence). The FDA label 2 emphasizes that midodrine's indication is based on surrogate markers (1-minute standing systolic BP), with clinical benefits not fully established, though it remains the only FDA-approved agent for symptomatic OH in the US 2, 10.
A 2013 meta-analysis 11 found insufficient evidence for midodrine efficacy on postural BP changes, though symptomatic improvement was significant. This highlights the importance of treating symptoms rather than BP numbers alone—continue therapy only if patients report significant symptomatic improvement 2.